Aug 25,2022

One Drop Improves Workplace Productivity for Older Adults with Type 2 Diabetes

One Drop, a leader in precision health solutions for people living with diabetes and other chronic conditions, today announced analyses from a randomized control trial (RCT) on the impact of its award-winning digital health platform on workplace productivity (presenteeism) among people with type 2 diabetes published in the Journal of Occupational Environmental Medicine (JOEM). Employees using One Drop experienced significant productivity and functioning gains and were less likely to experience presenteeism at follow-up compared to control groups.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jan 10,2023

Development and external validation of a machine learning-based prediction model for the cancer-related fatigue diagnostic screening in adult cancer patients: a cross-sectional study in China

This study aimed to create a CRF prediction model for cancer patients based on routinely obtained data from electronic health records (EHRs) using the 3P model, and externally validate the model with an independent dataset from another hospital. The study concluded that the 3P-based fatigue prediction model can accurately predict the risk of CRF, and that nonlinear algorithms such as Random Forest and Naive Bayes are more suitable for symptom diagnosis and evaluation.

CLINICAL STUDY

#rwd

#big data

#ml

View Analyst & Ambassador Comments
Go to original news
Jan 12,2023

Effects of virtual reality on physical, cognitive, and psychological outcomes in cancer rehabilitation: a systematic review and meta-analysis

The objective of this study was to comprehensively review the existing evidence on the effects of virtual reality (VR) in cancer rehabilitation, particularly in physical, cognitive, and psychological outcomes. The findings demonstrate that VR has promising effects in improving various aspects of cancer patients. Therefore, integrating VR into cancer rehabilitation programs can be a useful approach to alleviate functional limitations and impairments.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Jan 16,2023

Feasibility and pilot testing of a personalized eHealth intervention for pain science education and self-management for breast cancer survivors with persistent pain: a mixed-method study

A recent study involved the development and pilot testing of a personalized eHealth intervention to assist female breast cancer survivors in managing persistent pain after surgery. The research aimed to assess the acceptability, comprehensibility, and efficacy of the intervention. The study found that a personalized eHealth intervention containing a pain science education program and self-management support strategies was effective in managing persistent pain after breast cancer surgery. A controlled clinical trial is recommended to determine its effectiveness, and a full process evaluation is needed.

CLINICAL STUDY

#mobile app

#telehealth

View Analyst & Ambassador Comments
Go to original news
Jan 24,2023

How Real-World Data Helps Explore Alternative Dosing for Colorectal, Pancreatic Cancer Therapy

A joint effort between MedStar Georgetown Lombardi Comprehensive Cancer Center and COTA has demonstrated the feasibility of a patient-oriented dosing schedule for Stage 4 CRC/PC or locally advanced PC. This partnership showcases the contribution of real-world data to clinical research, which can provide insights into care that is currently being administered in clinical settings and help address critical questions.

CLINICAL STUDY

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Nov 11,2022

OncoHost to present proteomics-based biomarker model for clinical benefit to immunotherapy in NSCLC patients at SITC 2022

OncoHost has developed a novel predictive model for clinical benefit of immune checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients. The model is based on proteomic profiling of pre-treatment blood samples, combined with machine learning analysis that accurately predicts clinical benefit probability at twelve months, outperforming the predictive capabilities of the existing PD-L1 biomarker. The predictive model was developed on a cohort of 339 ICI-treated NSCLC patients taking part in OncoHost's ongoing, multicenter PROPHETIC clinical trial.

CLINICAL STUDY

#platform

#ai/software

View Analyst & Ambassador Comments
Go to original news
Nov 15,2022

Perspectives of older women with early breast cancer on telemedicine during post-primary treatment

Telemedicine has the potential to lessen healthcare burden of older patients due to frequent appointments, physical disabilities, and reliance on caretakers. To benefit from telemedicine, patients must have the capacity and willingness to engage with technology. This study aimed to better understand the telemedicine experiences of older women with non-metastatic breast cancer regarding visit convenience, completeness, and interpersonal satisfaction.

CLINICAL STUDY

#telehealth

View Analyst & Ambassador Comments
Go to original news
Nov 30,2022

Volpara Health software used in largest image quality evaluation to date

At the 2022 Radiological Society of North America (RSNA) Annual Meeting, Peter R. Eby, MD, of Virginia Mason Medical Center presented the results of the largest mammographic image quality evaluation to date, titled "Reduction in technical repeat and recall rate after implementation of artificial intelligence driven quality improvement software." This study highlights the potential for AI in revolutionizing what has traditionally been a very manual process, by providing continuous mammography image quality feedback to technologists on an unprecedented scale.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
Dec 01,2022

The Power of Collaboration: ASH Showcases COTA’s Real World Data and Research at Annual Meeting

COTA is honored to announce that our team has directly contributed to three abstracts accepted for poster presentation at the December conference. Two of these studies were conducted in close partnership with researchers from the FDA. Four other accepted abstracts leverage COTA’s real-world data (RWD) to support their crucial work around hematologic cancer.

CLINICAL STUDY

#rwd

View Analyst & Ambassador Comments
Go to original news
Dec 09,2022

Sarah Cannon Research Institute to Present Latest Research Insights at the 2022 ASH Annual Meeting & Exposition

Sarah Cannon Research Institute (SCRI), US Oncology Research (USOR), and Ontada announced that collectively more than 65 affiliated abstracts and presentations will be highlighted at the American Society of Hematology (ASH) Annual Meeting & Exposition from Dec. 10-13.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY